

Laguna Hills

Clinical Research Treatment Trial Flowchart

MYELOPROLIFERATIVE NEOPLASM: FRONT LINE

ETCTN 10538

Venetoclax+ASTX727 (All oral therapy) for CMML, PDS/MPN with excess blasts

Mechanism: BCL-2 selective inhibitor

PI: Jeyakumar
Coord: K. McAbee
Accrual: 0/5

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

CLL RELAPSED/REFRACTORY: 2L+

UCI 21-209

LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

PI: Coombs
Coord: S. Osorio
Accrual: 2/3

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs
Coord: S. Osorio
Accrual: 1/10

CRC: ADJUVANT

NRG G1008/CIRCULATE

(ctDNA guided tx)

PI: Zell

Coord: A. Luna

Accrual: 1/5

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 68/90